reported that the immune-related indices (CD4+/CD8+) and incidence of adverse reactions in the combination group were greater than those in the single treatment group and that KLX combined with DC-CIK could significantly improve the immune function of patients with advanced gastric cancer, alleviate clinical symptoms, mitigate the toxic side effects of chemotherapeutic drugs, and delay tumor progression (136). This evidence concerns the gene CD8A and neoplasm.